- Home
- ZNTL vs SMTI Comparison
ZNTL vs SMTI Comparison
Compare ZNTL & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | SMTI |
|---|---|---|
| Founded | 2014 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 182.6M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | SMTI |
|---|---|---|
| Price | $2.67 | $18.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.60 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 557.3K | 70.2K |
| Earning Date | 05-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.87 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,425,000.00 | $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $1.01 | $16.05 |
| 52 Week High | $3.95 | $35.70 |
Technical Indicators
Market Signals| Indicator | ZNTL | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 42.89 |
| Support Level | $1.29 | N/A |
| Resistance Level | $2.69 | $21.14 |
| Average True Range (ATR) | 0.21 | 1.20 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 32.46 | 41.03 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.